NSE: INDSWFTLAB CMP: Rs 205.35 P/E: 36.04x ROCE: 4.70% 6M Ret: +132.86% ATH: Rs 242.40 MCap: Rs 1783.53 Cr
Key Performance Indicators
Ind-Swift Labs. trades at Rs 205.35 on NSE (ticker: INDSWFTLAB), with a market capitalisation of Rs 1783.53 crore. The price-to-earnings ratio is 36.04x. Return on capital employed stands at 4.70%. The six-month price return is +132.86%. Quarterly net profit stands at Rs 15.11 crore, a year-on-year change of 9.35%. Quarterly sales are Rs 169.79 crore (+22.82% year-on-year). The all-time high is Rs 242.40, above the current price by 18.0%.
Highlights
Ind-Swift Labs. has delivered a six-month return of 132.86%, positioning it among the notable performers over the measured period in the healthcare sector. The all-time high of Rs 242.40 stands 18.0% above the current price of Rs 205.35, indicating the stock has corrected from its peak and sits below its historical ceiling. The market capitalisation of Rs 1783.53 crore at the current price classifies this as a mid-cap entity.
At a P/E of 36.04x, the stock trades at a moderate premium to the Indian market average, suggesting visible but not exceptional growth expectations. The ROCE of 4.70% — a low positive or negative reading requiring monitoring for improvement — provides a capital efficiency perspective that complements the P/E valuation framework.
Business Overview
Ind-Swift Laboratories is a pharmaceutical company manufacturing active pharmaceutical ingredients (APIs) and drug intermediate chemicals for domestic and international regulated markets. API manufacturers are the upstream segment of India's pharmaceutical value chain — producing the chemically active compounds used in finished dosage forms by formulation manufacturers globally. India's API sector has been strategically emphasised by the government following the pandemic's supply chain vulnerabilities, with PLI schemes supporting domestic API capacity expansion.
The quarterly profit of Rs 15.11 crore growing 9.35% year-on-year on revenues of Rs 169.79 crore (up 22.82%) demonstrates a profitably scaling pharmaceutical business. The P/E of 36.04 times is reasonable for an API manufacturer with demonstrated revenue growth. The ROCE of 4.70% is modest for a pharmaceutical company — typically capital-intensive — and should be tracked for improvement as revenues scale. The six-month return of 132.86% and the all-time high of Rs 242.40 — 18% above the current price of Rs 205.35 — indicate meaningful appreciation potential toward the historical peak.
Financial Analysis
Ind-Swift Labs.'s financial profile for the most recently reported quarter shows quarterly revenue of Rs 169.79 crore (+22.82% year-on-year) and quarterly net profit of Rs 15.11 crore (9.35% variation year-on-year). The positive quarterly profitability — even at modest absolute levels — provides a foundational earnings base from which P/E-based valuation can be meaningfully applied.
The ROCE of 4.70% is in the low-positive or negative range, which requires monitoring to assess whether the business model can generate returns above the cost of capital at scale.
At Rs 1783.53 crore market capitalisation, Ind-Swift Labs. has mid-cap institutional visibility with reasonable daily liquidity. Investors should access the company's quarterly results on BSE and any investor presentations for a comprehensive fundamental assessment.
Investor Highlights
The investment case for Ind-Swift Labs. is anchored in the healthcare sector's structural growth dynamics in India — expanding health insurance coverage, rising disease awareness, and government healthcare investment — combined with the company-specific momentum reflected in the 132.86% six-month return.
With the current price 18.0% below the all-time high of Rs 242.40, the stock presents a different risk-reward profile than entry at the peak. The key analytical question is whether the correction from the high represents a value opportunity — supported by maintained or improving fundamental performance — or an ongoing normalisation from a prior speculative overshoot.
The positive quarterly profitability provides a verifiable earnings anchor that supports P/E-based valuation and dividend capacity assessment — distinguishing Ind-Swift Labs. from the pre-revenue or loss-making entities in this collection where valuation is entirely expectation-dependent. Investors should track quarterly earnings trend data through BSE filings to assess whether the profit trajectory is improving, stable, or deteriorating relative to the current market capitalisation.
Frequently Asked Questions
Q: What does Ind-Swift Labs. do and what sector does it operate in?
A: Ind-Swift Labs. operates in India's healthcare sector, listed on NSE under ticker INDSWFTLAB. The company's specific products, services, and revenue model are documented in its annual report and exchange filings available through the BSE portal at bseindia.com. Investors should read these documents to form an accurate business understanding before drawing investment conclusions from price performance.
Q: What explains the six-month return of 132.86% for Ind-Swift Labs.?
A: The 132.86% six-month return reflects a combination of positive sector-level sentiment in the healthcare space, company-specific operational improvements visible in the financial data, and market re-rating of the company's growth potential. The positive quarterly profit of Rs 15.11 crore and revenue growth provide fundamental support for the appreciation. Specific fundamental triggers — contract wins, capacity additions, or strategic announcements — should be verified through BSE exchange disclosures.
Q: How should investors interpret the ROCE of 4.70% for Ind-Swift Labs.?
A: Return on capital employed of 4.70% measures the pre-tax profit generated per rupee of total capital deployed in the business. At 4.70%, the return on capital is low or marginally positive. Investors should monitor whether the ROCE is trending higher as revenues scale and operating leverage takes effect, or whether structural challenges in the business model limit returns.
Q: What is Ind-Swift Labs.'s current P/E and all-time high?
A: Ind-Swift Labs. trades at a price-to-earnings multiple of 36.04x at the current price of Rs 205.35. The all-time high price is Rs 242.40, which is 18.0% above the current price — indicating the stock has corrected from its historical peak.
Q: Where can investors find Ind-Swift Labs.'s official financial data?
A: Ind-Swift Labs.'s quarterly results, annual reports, shareholding patterns, and all material corporate disclosures are filed with the BSE and are freely available through the BSE corporate filing portal at bseindia.com. SEBI's listing regulations mandate disclosure of all financial results, board decisions, and significant corporate events within prescribed timelines. These filings are the authoritative source of verified financial and operational data for investment analysis.